H. Lundbeck A/S News Releases https://investor.lundbeck.com/ H. Lundbeck A/S News Releases en Lundbeck closes acquisition of Abide Therapeutics https://investor.lundbeck.com/news-releases/news-release-details/lundbeck-closes-acquisition-abide-therapeutics Press release Valby, 29 May 2019 Agreement gives Lundbeck a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s Syndrome. H. Lundbeck A/S (Lundbeck) has now closed the acquisition of US biotech company Abide Therapeutics Inc. Wed, 29 May 2019 07:00:08 +0200 H. Lundbeck A/S News Releases 18841 Lundbeck increases its share capital by 26,098 shares (0.0131 % of outstanding shares) as a result of exercise of employee warrants https://investor.lundbeck.com/news-releases/news-release-details/lundbeck-increases-its-share-capital-26098-shares-00131 Valby, Denmark, 22 May 2019 - H. Lundbeck A/S (Lundbeck) today announced that it has decided to increase its share capital by DKK 130,490 as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or Wed, 22 May 2019 10:38:44 +0200 H. Lundbeck A/S News Releases 18831 Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties https://investor.lundbeck.com/news-releases/news-release-details/transactions-shares-and-linked-securities-h-lundbeck-made-16 Valby, Denmark, 21 May 2019 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck. 1. Details of the person discharging managerial responsibilities / person closely associated Tue, 21 May 2019 13:47:42 +0200 H. Lundbeck A/S News Releases 18826 Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties https://investor.lundbeck.com/news-releases/news-release-details/transactions-shares-and-linked-securities-h-lundbeck-made-15 Valby, Denmark, 20 May 2019 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck. 1. Details of the person discharging managerial responsibilities / person closely associated Mon, 20 May 2019 14:18:35 +0200 H. Lundbeck A/S News Releases 18821 Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties https://investor.lundbeck.com/news-releases/news-release-details/transactions-shares-and-linked-securities-h-lundbeck-made Valby, Denmark, 9 May 2019 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck. 1. Details of the person discharging managerial responsibilities / person closely associated Thu, 09 May 2019 16:01:09 +0200 H. Lundbeck A/S News Releases 18806 Double-digit growth for all strategic brands and DKK 4,234 million in revenue and DKK 1,200 million in EBIT https://investor.lundbeck.com/news-releases/news-release-details/double-digit-growth-all-strategic-brands-and-dkk-4234-million HIGHLIGHTS Revenue reached DKK 4,234 million in the first quarter of 2019 representing a decline of 8% (6% in local currencies) compared to the same period last year. The decline was expected and a result of generic competition on Onfi ® Revenue of Abilify Maintena ® increased 27% to DKK 462 Wed, 08 May 2019 07:24:07 +0200 H. Lundbeck A/S News Releases 18801 Lundbeck to acquire Abide Therapeutics, adding a unique discovery platform and a lead compound in an exploratory phase IIa program for Tourette’s https://investor.lundbeck.com/news-releases/news-release-details/lundbeck-acquire-abide-therapeutics-adding-unique-discovery Abide’s world-class discovery platform is focused on harnessing the therapeutic potential of one of the largest and most diverse enzyme classes – the serine hydrolases (SHs) – with the potential to deliver unprecedented compounds across a broad range of central nervous system (CNS) indications Mon, 06 May 2019 07:26:57 +0200 H. Lundbeck A/S News Releases 18776 The Minister for Higher Education and Science and Lundbeck celebrate the future talents in brain research https://investor.lundbeck.com/news-releases/news-release-details/minister-higher-education-and-science-and-lundbeck-celebrate Press release                                                 The biggest talents in classes of natural sciences from 62 Danish high schools will today give presentations on their ideas for the future of brain research to the pharmaceutical company Lundbeck and the Minister for Higher Education and Fri, 26 Apr 2019 07:32:07 +0200 H. Lundbeck A/S News Releases 18766 Lundbeck held its Annual General Meeting on 26 March 2019 at the company’s registered office https://investor.lundbeck.com/news-releases/news-release-details/lundbeck-held-its-annual-general-meeting-26-march-2019-companys Valby, Denmark, 26 March 2019 - H. Lundbeck A/S (Lundbeck) announced today that the report by the Board of Directors was adopted and the annual report was approved at the annual general meeting. The proposal to distribute a dividend of 61% of the net profit for the accounting year 2018, Tue, 26 Mar 2019 14:16:10 +0100 H. Lundbeck A/S News Releases 18706 Lundbeck appoints Keld Flintholm Jørgensen as EVP and Chief Business Officer https://investor.lundbeck.com/news-releases/news-release-details/lundbeck-appoints-keld-flintholm-jorgensen-evp-and-chief Valby, Denmark, 8 March 2019 - H. Lundbeck A/S (Lundbeck) today announced the appointment of Keld Flintholm Jørgensen to the role of Chief Business Officer (CBO) heading Corporate Strategy & Business Development from 4 April 2019. Keld will be part of Executive Management in his role as Executive Fri, 08 Mar 2019 09:01:05 +0100 H. Lundbeck A/S News Releases 18686